Crystal violet Assay Kit (Cell viability)

Alternative names

3dopamine receptor, 5 HT2 receptor, 5-HT-2, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, 5-hydroxytryptamine 2A receptor, 5-hydroxytryptamine receptor 2A, 5HT2A_HUMAN, A2AAR, A2aR, AA2AR_HUMAN, ACLS, ACM3_HUMAN, ACM4_HUMAN, ACM5_HUMAN, AChR, AChR M5, ADA1D_HUMAN, ADA2A_HUMAN, ADA2C_HUMAN, ADENO, ADORA 2, ADORA2A, ADRA1A, ADRA1L1, ADRA2, ADRA2A, ADRA2L2, ADRA2R, ADRA2RL1, ADRA2RL2, ADRAR, ADRARL1, ADRARL2, AI413597, AI838772, AIS, ANDR_HUMAN, AR, AR8, ARO, ARO1, AW045860, AW493413, Acetylcholine receptor muscarinic 5, Adenosine A2 receptor, Adenosine A2a receptor, Adenosine receptor A2a, Adenosine receptor subtype A2a, Adra 2c, Adra1d, Adrenergic alpha 1A receptor, Adrenergic alpha 1B receptor, Adrenergic alpha 1C receptor, Adrenergic alpha 1D receptor, Adrenergic alpha 2A receptor, Adrenergic alpha 2C receptor, Adrenoceptor alpha 2C, Alpha 2 adrenergic receptor subtype C2, Alpha 2AAR subtype C10, Alpha 2B adrenoceptor, Alpha 2B adrenoreceptor, Alpha 2C adrenergic receptor subtype C4, Alpha adrenergic receptor 1b, Alpha adrenergic receptor 1d, Alpha-1A adrenergic receptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-1D adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-2 adrenergic receptor subtype C10, Alpha-2 adrenergic receptor subtype C4, Alpha-2-adrenergic receptor, renal type, Alpha-2A adrenergic receptor, Alpha-2A adrenoceptor, Alpha-2A adrenoreceptor, Alpha-2AAR, Alpha-2C adrenergic receptor, Alpha-2C adrenoceptor, Alpha-2C adrenoreceptor, Alpha-2CAR, Alpha-adrenergic receptor 1a, Alpha-adrenergic receptor 1c, Alpha-synuclein, Alpha-synuclein, isoform NACP140, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Aromatase, Atherosclerosis, susceptibility to, included, CHKM5MR, CHRM 3, CHRM1, CP19A_HUMAN, CPV1, CYAR, CYP19, CYPXIX, Cholinergic receptor muscarinic 1, Cholinergic receptor muscarinic 4, Cholinergic receptor muscarinic 5, Chrm 4, Chrm 5, Cyp19a1, Cytochrome P-450AROM, Cytochrome P450 19A1, Cytochrome P450, family 19, subfamily A, polypeptide 1, Cytochrome P450, subfamily XIX (aromatization of androgens), D(1A) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor, D1A dopamine receptor, D2 dopamine receptor, D2DR, D2R, DADR, DDPAC, DHTR, DKFZp686N23123, DNA binding protein, DRD 1A, DRD1_HUMAN, DRD2_HUMAN, DRD3_HUMAN, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), Dopamine D1 receptor, Dopamine D2 receptor, Dopamine D3 receptor, Dopamine receptor D2, Dopamine receptor D3, EGBRS, ER, ER-alpha, ER-beta, ERK-2, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ERT1, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, ETM1, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen synthase, Estrogen synthetase, Estrogen-related receptor alpha, Estrra, Extracellular signal-regulated kinase 2, FET1, FLJ11090, FLJ31424, FTDP 17, G protein beta1/gamma2 subunit interacting factor 1, GCPS, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, Gastric receptor 1, Gastric receptor I, Glioma associated oncogene family zinc finger 3, HDL cholesterol, augmented response of, to hormone replacement, included, HGNC:5183, HH2R, HM 3, HM 4, HM 5, HM1, HRH2_HUMAN, HTR 2, HTR 2A, HTR2, formerly, HUMARA, HYSP1, Histamine H2 receptor, Histamine receptor H2, IMD42, K-OR-1, KD, Kappa opioid receptor, Kappa-type opioid receptor, Kennedy disease (KD), LMOR, M-OR-1, M3 muscarinic receptor, M4, M5R, MAP kinase 1, MAP kinase 2, MAP kinase isoform p42, MAPK 1, MAPT, MAPTL, MGC104252, MGC104309, MGC105443, MGC110988, MGC112732, MGC127560, MGC129539, MGC134287, MGC138549, MGC156663, MGC41838, MGC64356, MK01_HUMAN, MOR, MSTD, MTBT1, MTBT2, Microsomal monooxygenase, Microtubule associated protein tau isoform 4, Microtubule-associated protein tau, Mitogen-activated protein kinase 1, Mitogen-activated protein kinase 2, Mtapt, Mu opiate receptor, Mu opioid receptor, Mu-type opioid receptor, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M4, Muscarinic acetylcholine receptor M5, Myocardial infarction, susceptibility to, included, NACP, NK-2 receptor, NK2R_HUMAN, NKNAR, NR1F3, NR3A1, NR3A2, NR3B1, NR3C4, Neurofibrillary tangle protein, Neurokinin 2 receptor, Neurokinin A receptor, Non A4 component of amyloid, Non-A beta component of AD amyloid, Non-A-beta component of alzheimers disease amyloid , precursor of, Non-A4 component of amyloid precursor, Non-A4 component of amyloid, precursor of, Nuclear receptor ROR-gamma, Nuclear receptor RZR-gamma, Nuclear receptor subfamily 1 group F member 3, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), OPRK 1, OPRK_HUMAN, OPRM1, OPRM_HUMAN, OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000058849, OTTHUMP00000161242, OTTHUMP00000161243, OTTHUMP00000162543, OTTHUMP00000198350, OTTHUMP00000218549, OTTHUMP00000218551, OTTHUMP00000218552, OTTHUMP00000218553, OTTHUMP00000218554, Oncogene GLI3, Opiate receptor kappa 1, Opioid receptor mu 1, Opioid receptor, kappa 1, Oprk2, P 450AROM, P38, P41, PAP A, PAPB, PARK 1, PARK 4, PHF-tau, PPD IV, PPND, PPP1R103, PRKM 2, PRKM1, Paired helical filament-tau, Parkinson disease (autosomal dominant, Lewy body) 4, Parkinson disease familial 1, Protein phosphatase 1, regulatory subunit 103, R21, RAR related orphan nuclear receptor variant 2, RAR related orphan receptor C, isoform a, RAR related orphan receptor gamma, RAR-related orphan receptor C, RDC 8, RNESTROR, RNPTAU, RORG_HUMAN, RP24-311F12.2, RZR GAMMA, RZRG, Retinoic acid binding receptor gamma, Retinoid-related orphan receptor-gamma, Rorc, SBMA, SCAN1, SKR, SMAX1, SNCA, SYN, SYUA_HUMAN, Serotonin receptor 2A, Seven transmembrane helix receptor, Snca synuclein, Snca synuclein, alpha (non A4 component of amyloid precursor), Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid hormone receptor ERR1, Substance-K receptor, Subtype alpha2 C4, Synuclein alpha, Synuclein alpha 140, Synuclein, alpha (non A4 component of amyloid precursor), TAC 2R, TAC R2, TACR 2, TACR2, TAU_HUMAN, TFM, TOR, TYDP, TYDP1_HUMAN, Tachykinin receptor 2, Tachykinin receptor 2 (substance K receptor; neurokinin 2 receptor), Tauopathy and respiratory failure, Tauopathy and respiratory failure, included, Testicular Feminization (TFM), Transcriptional activator GLI3, Transcriptional repressor GLI3R, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, Zinc finger protein GLI 3, alpha 2BAR, alpha-2-adrenergic receptor, platelet type, alpha2 AR C4, alpha2 C4, alpha2C, alpha2cii-adrenergic receptor, alphaSYN, androgen receptor splice variant 4b, cholinergic receptor muscarinic 3, dopamine receptor D1, estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, hA2aR, hERR1, hMOP, m3 muscarinic acetylcholine receptor, m5, muscarinic 3, muscarinic cholinergic m3 receptor, muscarinic m3 receptor, p42-MAPK, pTau, protein kinase, mitogen-activated, 1, protein kinase, mitogen-activated, 2, protein tyrosine kinase ERK2, serotonin 5-HT-2 receptor, formerly, serotonin 5-HT-2A receptor